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ABSTRACT
Prescription opioid misuse has become a growing problem in the United States,
and there has been a significant increase in the number of nonfatal overdose and overdose
deaths since the 1990s. Idaho has also experienced an increase in the number of druginduced deaths over time, increasing nearly 30% from 2012 to 2016. The Centers for
Disease Control and Prevention indicates overprescribing and dispensing of prescription
opioids is a main driver to the increase in overdoses. Evidence-based early intervention
methods, such as screening, brief intervention, and referral to treatment (SBIRT), can be
utilized in healthcare settings to identify risky behaviors among individuals who may not
be seeking help for substance problems. However, limited research has been done to
examine SBIRT in a pharmacy setting and in pharmacist perceptions toward performing
SBIRT for prescription opioid misuse.
The purpose of this study was to develop an instrument based on the Theory of
Planned Behavior (TPB) to measure pharmacist perceptions toward using SBIRT for
prescription misuse and then test initial validity and reliability. To construct appropriate
questions, survey items for attitude, subjective norms, perceived behavioral control, past
behavior, and intention were developed from a previous TPB instrument on the
utilization of the prescription monitoring program. After data was collected,
psychometric testing was initiated and included factor analysis, testing the internal
consistency of the subscales, and a correlation to determine the degree of similarity
between subscales. A Principal Component Analysis (PCA) was used to extract factors in
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this study with a non-orthogonal rotation (Direct Oblimin). Items were retained if they
loaded onto a factor at |0.4| or higher. Findings supported the eight-factor solution that
was conceptually hypothesized with strong internal consistency for each construct.
Cronbach’s alpha scores were 0.7 and above for all factors except for past behavior.
These results offer a foundation for future research to build on the instrument and inform
interventions that may shape pharmacist readiness in prescription misuse early
intervention strategies.
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CHAPTER ONE: INTRODUCTION
Prescription opioid misuse has become a growing problem in the United States,
and there has been a significant increase in the number of overdose and overdose deaths
since the 1990s. According to the Centers for Disease Control and Prevention (CDC),
two out of three drug overdose deaths involved prescription or illicit opioids (Hedegaard,
Miniño, & Warner, 2018). Idaho has also experienced an increase in the number of druginduced deaths over time, increasing nearly 30% from 2012 to 2016 (Drug-Induced
Deaths: Idaho Residents 2016 summary, 2017). The CDC indicates overprescribing and
dispensing of prescription opioids is a main driver to the increase in overdoses.
Statement of the Problem
According to the National Survey on Drug Use and Health (NSDUH), Idaho’s
estimated 2015-2016 prevalence of pain reliever misuse in the past year was 5.09% for
ages 12 years and up, and the rate was even higher for those 18-25 years of age (9.77%),
both exceed the estimated national rates. Additionally, NSDUH estimated approximately
104,000 people ages 12 years old and up to have a substance use disorder (SUD) in
Idaho, and yet 96,000 Idahoans needed but did not receive treatment in a specialty facility
for SUD (National Survey for Drug Use and Health, 2015-2016). Although NSDUH
found the majority of people who misused prescription pain relievers in the past year
obtained the medication from a friend or relative (53%), 35.4% obtained the pain
medication through a prescription(s) from a provider.
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Evidence-based early intervention methods, such as screening, brief intervention,
and referral to treatment (SBIRT), can be utilized in healthcare settings to identify risky
behaviors among individuals who may not be seeking help for substance problems
(Substance Abuse and Mental Health Services Administration 2011). As part of a teambased approach, pharmacists have the potential to mitigate harm in instances of early
prescription opioid misuse before risky behavior reaches a diagnosable level.
Purpose of this Study
The focus of this research was to develop an instrument that could accurately
assess community pharmacists’ perceptions towards performing SBIRT in their practice
setting. This was completed by adapting a Theory of Planned Behavior (TPB)
questionnaire used to examine pharmacists’ perceptions toward utilizing the Prescription
Monitoring Program (PMP) for opioid misuse and administering a pilot study to perform
initial psychometric tests. The TPB constructs in the instrument examine attitude,
subjective norms, and perceived behavioral control in relation to behavioral intention and
past behavior.
Justification of the Study
Misused medications are often obtained through a pharmacy (Cicero et al., 2011).
Additionally, pharmacists are considered the most accessible and trusted health
professional whose doctorate-level training can help address gaps in primary care,
especially in health professional shortage areas (Manolakis & Skelton, 2010). There is
promising research on the effectiveness of SBIRT in reducing risky alcohol and
substance use behaviors and improving short-term health outcomes (United States, 2012).
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However, limited research has been done to examine SBIRT in a pharmacy setting and in
pharmacist perceptions toward performing SBIRT for prescription opioid misuse.
Research Questions
The purpose of this study was to develop a valid and reliable instrument based on
the Theory of Planned Behavior to measure pharmacist perceptions toward deploying
SBIRT for prescription misuse. Therefore, the overall research question was: can the
instrument that measures the constructs in TPB be reliable and valid? From this overall
research question, three additional research questions were created:
1. Does the instrument achieve face and content validity?
2. Are the attitude, subjective norms, perceived behavioral control, intention, and
past behavior subscales internally consistent?
3. Do the underlying factor structures in the subscales support the theoretical
framework?
Findings from this study will inform future psychometric testing on the
instrument and potential points of education that would build readiness to implement
SBIRT in a pharmacy setting.
Delimitations
1. The study was conducted on licensed pharmacists practicing in the state of Idaho
at the time of the study.
2. Participants included actively practicing pharmacists that were registered to the
Idaho Board of Pharmacy’s Prescription Monitoring Program (PMP) database
with an active email address.
3. Data were collected from March -April 2019.
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Limitations
1. The survey instrument was adapted from a Theory of Planned Behavior
questionnaire used in two previous studies rather than eliciting measures
through qualitative methods.
2. There was no previous study or instrument to compare results to for
concurrent validity or test-retest reliability.
3. Data were self-reported and responses may not have been candid.
4. Participants that responded to the survey may not have been representative of
all pharmacists practicing in Idaho.
5. Participants may have different understandings of the Screening, Brief
Intervention, and Referral to Treatment practice.
Assumptions
1. Survey items that were adapted in this study were based on utilization of the
Prescription Monitoring Program, which can be considered the first step to
screening for misuse. The intended audience, context, and time of the
behavior remained the same.
2. Definitions were provided in the instrument to provide a basic understanding
of the SBIRT steps.
3. Data collected in this pilot would be useful for further instrument
psychometric testing and future SBIRT training and piloting implementation
in a pharmacy setting.
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Definition of Terms
•

Community pharmacy: Pharmacy practiced in various retail settings
such as independent pharmacies, chain stores, food stores, where
prescription orders are dispensed outside an inpatient hospital setting that
allows the public access to medications when needed.

•

SBIRT: Screening, Brief Intervention, and Referral to Treatment is a
comprehensive, evidence-based public health approach used to identify,
reduce, and prevent problematic use, abuse, and dependence of alcohol
and drugs. It is useful in disrupting the development of use disorders.

•

Screening: Use of a validated universal tool to quickly assess a patient for
risky substance use behaviors, and who may already have a substance use
disorder, and identify appropriate level of intervention.

•

Brief Intervention: A time-limited strategy where a healthcare
professional engages patients showing risky behaviors in a short
conversation with a focus on increasing insight in substance use and
motivating change.

•

Referral to Treatment: In instances where more advanced treatment is
necessary, a healthcare professional provides a referral to brief therapy or
a higher level of care when a patient’s screen indicates additional services.
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CHAPTER TWO: LITERATURE REVIEW
This chapter provides information on the role of a community pharmacist in the
opioid crisis. This chapter will also review the literature relevant to this study on
Screening, Brief Intervention, and Referral to Treatment, SBIRT in a pharmacy setting,
and the Theory of Planned Behavior.
Community Pharmacists in the Opioid Crisis
Community pharmacists remain one of the most accessible health professionals in
the healthcare system and are often under-utilized in a public health capacity. Among
many tasks, community pharmacists are frontline professionals responsible for dispensing
medications, ensuring the legitimacy of prescriptions, monitoring drug utilization, and
maintaining links with primary care and other health professionals (World Health
Organization, 1988). The role of pharmacy has evolved from traditional dispensing
practices to support public health initiatives through providing immunizations (Ndiaye et
al., 2003) and health screenings such as influenza testing (Klepser et al., 2018). In some
states, the pharmacist’s role has also expanded to medication therapy management
(Casserlie & Mager, 2016) and chronic disease state management (Schuessler, Ruisinger,
Hare, Prohaska, & Melton, 2016). Today, amidst the public health crisis in opioid-related
overdoses, the American Society for Health-System Pharmacists (ASHP) supports
pharmacists’ active involvement in reducing the negative effects substance misuse has on
society, health systems, and the pharmacy profession (2016).
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As part of a comprehensive approach, several national pharmacy organizations
have stressed the importance of the pharmacist’s role in responding to the opioid crisis
due to their expertise and accessibility. Pharmacists are well positioned to exercise
professional judgment to balance patients’ legitimate medical need for prescription
opioids with the need to prevent diversion, misuse, dependence, and substance use
disorders (American Pharmacists Association, 2018; The College of Psychiatric and
Neurologic Pharmacists, 2016). One study found that 86% of the pharmacists surveyed
had concerns about prescription opioid use in several patients, and the number of patients
they were concerned about was positively correlated to the number of patients on opioids
for chronic pain (Kahan et al., 2011). In addition to educating and counseling patients on
safe use, storage, and disposal of medications, pharmacists have access to screening tools
such as the Prescription Monitoring Program (PMP). The PMP allows pharmacists to
verify the validity of a prescription and assess for “red flags” in prescribing or dispensing
history. An educational document published by the College of Psychiatric and Neurologic
Pharmacists, Opioid Use Disorder: Interventions for Community Pharmacists (2016),
outlines additional strategies for public-facing pharmacists to deploy. These strategies
include increasing access to naloxone (an opioid overdose reversal medication),
developing an intervention resource list for patients, and talking with patients about SUD.
To reduce the risk of diversion and opioid-related overdoses, pharmacies have also
participated in and promoted medication take-back programs to reduce the amount of
available controlled substances (Strand, Eukel, & Burck, 2019).
While the aforementioned efforts have made an impact on the opioid crisis for
diversion and individuals who may have a SUD, more pharmacy-involved interventions
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need to focus on preventive patient care. Proactive approaches utilizing pharmacists in
underserved rural areas are particularly important where individuals have a higher risk for
opioid misuse than their urban counterparts (Cochran, Engel, Hruschak, & Tarter, 2016).
Furthermore, ASHP supports pharmacists in the identification of patients who may have
substance misuse problems and referring those patients to appropriate resources for
further evaluation and treatment (2016).
Screening Brief Intervention and Referral to Treatment
Screening, brief intervention, and referral to treatment (SBIRT) is a public health
approach to early intervention for risky alcohol, tobacco, and other substance use
behaviors (SAMHSA, 2011). SBIRT is based on the Institute of Medicine report that
recognized substance use occurs on a continuum of severity and calls for integrated
service systems to fill gaps between primary prevention and intensive treatment for SUD
(1990). SBIRT is designed for use by professionals who do not specialize in addiction
treatment and is relatively easy to learn by diverse health professionals. In 2003, SBIRT
was funded across the U.S. by the Substance Abuse and Mental Health Services
Administration (SAMHSA) in various settings such as primary care offices and college
campuses (SAMHSA, 2011). The SBIRT model uses three basic elements in the process:
(1) universal screening, (2) if screening indicates moderate risk a brief intervention is
used to motivate change in behavior, and (3) a referral to treatment or additional services
if the screening indicates high-risk behavior.
A brief universal screening, typically taking about 5-10 minutes to complete,
addresses specific behaviors. Because the screening is done with all patients and takes
little time, professionals working in busy practices may more generally accept SBIRT
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(SAMHSA, 2011). If individuals screen positive, then the brief intervention uses
motivational interviewing to provide feedback and advice to facilitate behavior change.
The screening process may also assist in connecting patients to preventive services such
as diversion reduction services, access to naloxone, and coordination of care services
(Pringle, Cochran, & Aruru, 2019). In instances when individuals screen for substance
dependence or a use disorder, a referral to a specialty treatment provider should be made.
In a primary care setting, approximately 5%-20% of screened patients are positive for
some level of substance misuse and only 3%-4% need to be referred (SAMHSA, 2011).

Universal Screening (AUDIT,
DAST-10, PHQ2)

The flow for the SBIRT process is shown in Figure 2.1.

Negative

Provide Positive
Reinforcement
Low Risk: Provide Brief
Intervention

Positive

Moderate Risk: Provide Brief
Intervention & Brief
Treatment
Harmful Use, Depedency:
Provide Referral to
Treatment

Figure 2.1

Flow Chart for the SBIRT process
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Effectiveness of SBIRT
There is substantial research that supports the efficacy of SBIRT at reducing
hazardous alcohol use (Beich, Thorsen, & Rollnick, 2003; Bien, Miller, and Tonigan,
1993; Kaner et al., 2009) and a growing body of research that supports the effectiveness
at reducing substance use (Barbor, Del Boca, & Bray, 2017). Similar to alcohol use, licit
and illicit substance use conditions can occur across a continuum of severity but are
typically only identified and treated when it becomes severe. In respect to prescription
misuse, Zahradnik et al. (2009) found that brief intervention led to a reduction in
prescription drug consumption, including opioids.
SBIRT in Pharmacy
Pharmacists frequently encounter patients at risk for prescription misuse,
dependence, diversion, and use disorders. Leong, Alessi-Severini, Sareen, Enns, and
Bolton (2016) found that the most common reasons a patient would request an early
prescription opioid refill or duplication of prescription refills are lost medication, going
out of town, and stolen medications. While the majority of pharmacists denied the
prescription refill, factors such as familiarity with the patient and easy access to medical
history facilitated the filling request. Pharmacists are well positioned to utilize SBIRT to
inform the decision-making process in instances of early refill requests and to identify
potential opioid misuse in their practice. SBIRT is versatile, brief, and easy to learn.
However, unlike the extensive research on use in a primary care setting, few studies have
reviewed the SBIRT model in a pharmacy setting.
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Screening
Of the emerging studies on SBIRT-type strategies in a pharmacy setting, many
investigate screening and/or brief intervention (SBI) or referral to treatment. A survey
administered to Utah and Texas pharmacists found a high level of interest in helping
patients with prescription opioid use problems, with 50.2% of respondents agreeing that a
pharmacy would be a good setting to test if screening and brief intervention could help
patients misusing prescription opioids. Additionally, over 40% of the surveyed
pharmacists indicated they already screen for prescription opioid misuse (Cochran, Field,
Lawson, & Erikson, 2013). Authors note that pharmacists’ interest and their practice
setting are important factors to consider when implementing pharmacy-based misuse
interventions. A 2015 study conducted by Cochran, Field, and Lawson found that
practicing in a chain pharmacy was the strongest predictor of screening, and pharmacists
who did screen had practiced, on average, three years longer than those who did not
report screening. Pharmacists who reported feeling awkward inquiring about prescription
opioid misuse in patients were 58% less likely to screen, and those who had inadequate
access to screening tools were 44% less likely to report screening. In contrast,
pharmacists indicated quick and easy screening tools would motivate them to work with
patients who misused medications (Cochran et al., 2015). Pharmacists who felt electronic
prescription record systems were useful as a screening tool were also 75% more likely to
screen at the time of the study (Cochran, Field, & Lawson, 2015).
A 2019 study assessed the feasibility of community pharmacists screening
patients using the Opioid Risk Tool, a validated tool used in pain clinics, to identify
opioid misuse. If patients screened positive, the pharmacists offered services including
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counseling patients on the potential for SUD. The six-week pilot study showed that, of
the 107 patients screened, 25% were identified at some risk of misuse, similar to rates in
other settings. Of the patients screened, 71 received information about medication takeback programs and 17 were provided information on community support services (Strand
et al., 2019). Preliminary research on screening for opioid misuse and use disorder in a
community pharmacy setting found that an objective assessment helped identify patients
at risk for misuse and facilitate a discussion on use disorders (Strand et al., 2019).
Additionally, screening for misuse increased the likelihood of discussing potential opioid
misuse (Cochran et al., 2015). Leong et al. (2016) found that nearly 50% of pharmacists
felt confident in their ability to identify high-risk patients for prescription misuse;
however, 44% of respondents felt they were not confident in their ability to intervene if
they did suspect misuse.
Brief Intervention
Regarding providing a brief intervention, chain pharmacists were again the largest
group that reported currently engaging patients in a discussion on prescription opioid
misuse while hospital system pharmacists were the least likely group (Cochran et al.,
2015). Authors also found that pharmacists who held a bachelor-level degree were the
largest group currently discussing misuse with patients (54.8%) while doctorate-level
pharmacists were the largest group who did not discuss misuse (50.5%).
In 2018, Riley and Alemagno evaluated patient and pharmacist acceptability of
five opioid misuse interventions in Ohio. Two of the five interventions included
counseling patients on the risks associated with opioid misuse (brief intervention) and
referring patients to treatment programs. Patients and pharmacists alike demonstrated
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some level of support for counseling on risks associated with opioid misuse. However,
only 32% of patients indicated that a pharmacist had ever counseled them on proper
prescription opioid use and potential risks like an addiction (Riley & Alemango, 2018).
From the pharmacists’ perspective, the depth of the patient-pharmacist relationship may
affect the decision to engage in a discussion about prescription misuse (Hagemeier et al.,
2016).
Referral to Treatment
In respect to referring patients to treatment, Riley and Alemango (2018) found
that both patients and pharmacists reported more cautious support. Authors also asked
pharmacists if they have ever referred a patient to local treatment resources, and
interestingly, 25% of pharmacists reported they had at least once in their professional
career. However, only 1.6% of patients reported receiving treatment resources from a
pharmacist. Similarly, Hagemeier, Alamian, Pack and Murawski (2014) found that
approximately 25% of 637 Tennessee community pharmacists surveyed have previously
provided addiction treatment facility information to patients and only 13% had addiction
treatment facility information readily available. Hagemeier et al. (2014) also found an
association in pharmacists providing addiction treatment facility information to patient(s)
with being male, increased number of hours worked per week, having information readily
available in their pharmacy, higher self-efficacy beliefs, and participation in prescription
opioid abuse-specific continuing education. Unlike both screening and brief intervention,
pharmacists employed in a chain or grocery store setting were significantly less likely to
provide treatment information than pharmacists in an independent setting were.
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Barriers and Facilitators to SBIRT
Several studies indicated barriers to effectively use SBIRT-type interventions in a
pharmacy setting. First, the need for additional training and education surfaced as a
barrier (Cochran et al., 2015; Lafferty, Hunter, & Marsh, 2006). Pharmacists were less
likely to discuss prescription misuse with patients if they felt they had too little training in
addiction and helping patients with substance use disorders (Cochran et al., 2014;
Wenthur et al., 2013). A survey administered to Florida pharmacists found that only 38%
of respondents indicated having “much” to “very much” knowledge about addiction as a
disease (Lafferty et al., 2006). Additionally, 46.9% of pharmacists reported rarely or
never counseling patients on addictive medication even though similar rates (46.7%)
were reported of having “much” knowledge about counseling and intervening in misuse
(Lafferty et al., 2006). Based on these findings, authors note pharmacists should stay upto-date on appropriate interventions for substance abuse and treatment resources for
substance use disorder. Wenthur et al. (2013) found that both student pharmacists and
practitioners were interested in additional addiction education, and many believed it
would positively affect their ability to counsel patients and better use local treatment
resources. When it came to practicing pharmacists, 75.7% of respondents felt the
pharmacy curriculum needed to include drug withdrawal and treatment, available
addiction resources (57.9%), intervention (40.5%), and recovery options (43.7%)
(Wenthur et al., 2013). Even though student pharmacists rated it lower in importance than
practicing pharmacists, student pharmacists also rated addiction-related topics as high
importance. Interestingly, the more practice experience gained in both students and
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practitioners, the more important addiction-related topics became to them (Wenthur et al.,
2013).
Confidence also emerged as a potential barrier to performing behaviors in SBIRT.
Hagemeier et al. (2014) found that the majority of pharmacists were confident in their
ability to identify misuse in patients, but few were confident in their interpersonal skills
regarding prescription misuse. Pharmacists appear more confident in their ability to
screen for or detect misuse and less confidence in their ability to briefly intervene with a
discussion about addiction (Hagemeier et al., 2014; Lafferty et al., 2006). Furthermore,
only 18% of respondents were confident in their ability to detect misuse, discuss misuse
with patients, counsel on addiction, and discuss treatment options with patients. The
number of years practiced, practice setting and gender appeared to influence confidence.
Additionally, pharmacists who felt they had a right to ask about misuse were twice as
likely to engage patients in a discussion about it (Cochran et al., 2015). Pharmacists who
felt their patients believed the pharmacists had a right to ask were 88% more likely to
discuss misuse.
Pharmacists also identified employer type as a potential barrier to screening and
briefly intervening, particularly in chain or supermarket practice settings, and fear from
employer repercussions (Hagemeier et al., 2014). In addition to employer type, fear of
patient’s response, personal safety, quick easy access to tools and information, and time
constraints were identified as barriers (Hagemeier et al., 2014; Hagemeier et al., 2016;
Cochran et al., 2015; Fleming, Bapat, & Varisco, 2019).
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Theoretical Framework: Theory of Planned Behavior
The Theory of Planned Behavior (TPB), based on the Theory of Reasoned action,
is a theoretical model used to predict individual behaviors (Ajzen, 1991). The TPB is
designed to examine the relationships between intentions, behaviors, perceptions,
attitudes, and motivations. TPB posits that behavioral intention determines actual
behavioral performance, and Ajzen (1991) states that intention can be determined by
three constructs: attitude, subjective norms, and perceived behavioral control. In this
context, attitude can be defined as the “degree to which a person has a favorable or
unfavorable evaluation or appraisal…” towards the behavior (Ajzen, 1991). Subjective
norms are the perceived social pressure from close personal and professional
relationships to perform or not perform the behavior. Lastly, perceived behavioral control
is the perceived ease or difficulty of doing that behavior by reflecting on past experiences
and anticipating future obstacles or difficulties (Ajzen, 1991). TPB is an appropriate
theory to explore beliefs that may facilitate or deter pharmacists’ adopting SBIRT as an
early intervention.
Ajzen and Fishbein (1980) recognize external factors that can also influence
behavioral intention and performance but are not considered a construct in the model.
External factors include demographics like age, gender, and education level. The TPB
also assumes that individuals will have the resources and opportunity to perform the
behavior in question. According to Ajzen (1991), TPB can be modifiable and additional
variables can be included in the model. Consequentially, this study will also include
perceived contextual barriers in addition to attitude, subjective norms, and perceived
behavioral control. See Figure 2.2 for the TPB conceptual model used in this study.
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Figure 2.2

Theory of Planned Behavior Model

Theory of Planned Behavior in a Pharmacy Setting
Previous studies have used the TPB to gain a better understanding of health
professionals’ behaviors and to investigate perceptions across a broad range of behaviors
(Armitage & Conner, 2001). TPB has been utilized as a theoretical framework in several
prescription drug misuse studies in pharmacy including intention to utilize the PMP
database (Fleming et al., 2014; Gavaza, Fleming, & Barner, 2014), intention to provide
medication disposal education (Tai, Hata, Wu, Frausto, & Law, 2016), and intention to
report adverse drug events to the FDA (Gavaza & Bui, 2012). The TPB has also been
used to explore pharmacist perceptions and behavioral intention toward the three
behaviors in SBIRT. For example, a Tennessee study used the TPB to explored
pharmacists’ perceptions toward initiating communication with patients about
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prescription drug misuse and if they see it as their role to potentially intervene in
circumstances such as use disorders (Hagemeier et al., 2014). However, no single study
has explored all three SBIRT behaviors in a pharmacy setting using the TPB.
Conclusion
Pharmacists are encouraged to address and respond to the increase in prescription
drug misuse, and the research indicates that some pharmacists already occasionally
screen, briefly intervene, or refer patients to treatment for substance misuse. Studies that
have explored pharmacists’ perceptions towards intervening indicates that quick and easy
access to tools and information influence their decision to screen, briefly intervene, and
refer to treatment. Previous studies also suggest that pharmacists may experience practice
setting-related or personal barriers to using SBIRT. These barriers listed in the research
include gender, education, experience, time constraints, and fear from employer or
patients’ reactions. Despite emerging research evaluating the possibility of SBIRT in a
pharmacy setting, it is still largely unknown what pharmacists’ perceptions toward
implementing all steps in the evidence-based practice are for prescription misuse.
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CHAPTER THREE: METHODOLOGY
Introduction
This chapter describes the research methodology used in the design, construction,
and evaluation of the survey tool. The first section details the first steps in conceptual
design and instrument development. The second section details the data collection phase
including the process to disseminate the test survey and sample participants. The final
section describes the process for data analysis, specifically testing the reliability and
validity of the survey tool. The proposal of this study was approved by Boise State
University’s Institutional Review Board (Appendix A).
Instrument Design
The survey instrument development was done in three steps. These steps include
(1) defining behavior and research population (2) adapting items from a previously
reviewed TPB survey instrument, and (3) submitting the proposed items to a panel of
expert reviewers to ensure content validity.
Defining Behaviors
Fishbein and Ajzen (2010) instruct the first step as clearly defining the behavior
of interest in terms of target, action, context, and time (TACT). Specifically applied to
pharmacists currently practicing in Idaho and accessible to the public, the TACT goes as
follows: pharmacists (target) Screening Brief Intervention and Referral to Treatment
(action) to identify and provide early intervention for nondependent risky behaviors in the
pharmacy (context) when patients pick up their prescription (time). For this study, SBIRT
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was divided into three behaviors (1) screening for risky behaviors, (2) briefly intervening
with feedback and advice, and (3) referring to treatment if needed.
Identifying Survey Items and Scale
Secondly, to construct appropriate questions, survey items for attitude, subjective
norms, perceived behavioral control, past behavior, and intention were developed based
on the TPB instrument from Gavaza et al. (2014). Gavaza, Fleming, and Barner’s (2014)
TPB instrument items were developed from focus groups and elicitation interviews with
pharmacists in Texas on intention to utilize the Prescription Monitoring Program (PMP)
to help identify diversion or other controlled substance misuses (Fleming et al., 2014).
Items were adapted to reflect each behavior in SBIRT to capture if pharmacists’
perceptions varied across each step in the process. A matrix of TPB constructs and
SBIRT questions can be found in Appendix C.
Additionally, 11 demographic items and one question to capture perceived
barriers were added to the instrument. Barriers to counseling patients with mental health
disorders by Panesar (2016) were used to inform perceived barriers in this study.
Demographic items included gender, age, education level, practice setting, number of
years practicing pharmacy, number of hours working in a community setting, and
estimated opioid prescriptions filled in a week. Attitude was made up of 9 items, 30 items
for subjective norms, 11 items for perceived behavioral control, and 12 items for past
behavior and intention. All items for the TPB construct used a 7-point bi-polar scale
ranging from extremely unlikely (-3) to extremely likely (+3) with 0 being neutral
(Glanz, Lewis, & Rimer, 1997). The survey instrument included 74 items to capture
perceptions for the three SBIRT behaviors and demographics.
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Content Validation
Expert opinions were solicited to aid in assessing the content validity and clarity
of the survey instrument. Five individuals made up the expert panel – four individuals
with pharmacy background and expertise and one professional with expertise in
substance abuse prevention and health behavior theory. These experts were chosen
because each has an interest and worked with substance misuse issues in different
capacities. Each reviewer was sent an email with information on the purpose of the study
and the survey items, including demographics, to provide comments and feedback on.
Revisions were made to the survey items based upon the feedback and comments from
the reviewers. Subjective norms questions were narrowed from 30 items to 18 items,
combining “friends” and “family” into a single item instead of two separate categories.
Feedback from reviewers also indicated that two items in perceived behavioral control
were duplicative and therefore were removed. Lastly, perceived contextual barriers were
reduced to 18 possible barriers with the option for participants to write in a barrier.
Survey Pilot
The survey instrument was also pretested with a cohort of Master of Health
Science (MHS) students. Students enrolled in Program Evaluation were sent a test link to
access the Qualtrics survey. Students were asked to complete the survey and provide
feedback on language, survey design, and use of the TPB. Based on feedback from the
MHS students and the expert panel, revisions were also made to the wording in perceived
behavioral control and attitude, and definitions of each SBIRT behavior were added for
participants.
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Finalized Survey
In total, 60 items made up the finalized survey instrument. There were 11
demographic items, 9 items to capture attitude, 18 items for subjective norms, 9 items for
perceived behavioral control, 12 items for past behavior and intention, and one item for
perceived barriers. The survey instrument is provided in Appendix D.
Data Collection
Participants
Study participants included pharmacists currently practicing in the state of Idaho
and were registered for the Idaho Prescription Monitoring Program (PMP), a statewide
electronic database that tracks data on dispensed controlled substances. The Idaho Board
of Pharmacy provided a contact list for pharmacists registered to Idaho’s PMP. For this
study, pharmacists who practice in a hospital setting were excluded from the list to focus
on those most easily accessible to the public. However, the BOP does not require
pharmacists to be employed to hold a valid Pharmacist license in Idaho. Additionally, the
employment status of the pharmacist does not necessarily restrict or grant access to the
public. For example, a pharmacist shown to work in a hospital setting may also be
accessible to the public as a freelance pharmacist or with the permission of the hospital
while working at the hospital. A demographic question on current practice setting to
identify pharmacists who are registered for the PMP but not practicing (i.e. retirement)
was used to exclude those responses in the analysis. With the exclusion criteria, there
were 1,330 pharmacists on the distribution list.
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Data Collection Procedures
An introductory message and link to the pilot survey were distributed
electronically to the list of pharmacists provided by the Idaho BOP. The introduction
message (Appendix B) included a summary of the study, eligibility to participate, time
expected to complete the online survey, and consent to participate. The survey was
created, distributed, and collected using Qualtrics. The period for data collection was
between March 12 and April 18, 2019. A soft distribution to approximately 10% of the
sample (n=130) was used the first week to correct any issues and the remaining email
distributions were sent 7 days later. Three email reminders were emailed to unfinished
respondents. To maintain privacy and confidentiality, all data was collected anonymously
and no identifying information was obtained. The data was stored in a passwordprotected online database until the end of the survey period.
Data Analysis
After data was collected, psychometric testing was initiated. Statistical analyses
included factor analysis, testing internal consistency reliability of the subscales, and a
correlation to determine the degree of similarity between subscales.
Factor Analysis
A factor analysis was performed to identify factor structure. An Exploratory
Factor Analysis (EFA) was used to determine if the 48 TPB items followed the
underlying constructs of the theory and if the items hang together in each of the
subconstructs. A Principal Component Analysis (PCA) was used to extract factors in this
study with a non-orthogonal rotation (Direct Oblimin). Overall, eight factors were
requested based upon the theoretical design of the instrument to index: attitude behavioral
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intention, attitude evaluation, subjective norms motivation to comply, subjective norms
normative belief, perceived behavioral control control belief, perceived behavioral
control perceived power, behavioral intention, and past behavior.
There were three criteria used to determine factor retention in the analysis. The
first criteria was the Kaiser-Meyer-Olkin (KMO) measure used to verify sampling
adequacy and Bartlett’s test of sphericity to test if the variables are correlated enough for
factor analysis. An acceptable KMO limit was established at 0.5 or above while the
Bartlett test should be significant, meaning less than 0.05 (Morgan, 2013). Secondly,
Cattell’s scree plot was used to determine at what point a factor explains little variance.
In the scree plot, each subsequent factor explains less variance than the factor before it.
Typically below the “elbow” of the plot factors will explain little variance whereas above
the “elbow” factors explain considerably more variance. Lastly, interpretability criteria
including if there were at least three item loadings onto a factor at a significant level, if
the variables share a conceptual meaning, if the other factor loadings appear to measure a
different construct, and if there were either high or low loadings onto a factor (Suhr,
2006). Although significant levels are just guidelines, low factor loadings would typically
be below |0.30|, but setting the level at |0.50| or above is atypical (Morgan, 2013).
Therefore, a significant level for an item to load onto a factor was established at |0.40| or
greater.
Reliability
Cronbach’s coefficient alpha, a preferred indicator, was then used to test
reliability of the survey items (Cohen, 2003). According to Morgan (2013), alpha is
commonly used to indicate the internal consistency of multi-scale items when the survey
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has been administered once, such as this case. Cronbach’s alpha is determined by the
average correlation of each item in the scale with every other item. An acceptable alpha
score should be 0.70 or higher (Morgan, 2013).
Correlation
A Pearson-r correlation was performed on the TPB subscales to examine the
relationships between the constructs and determine if there was a significant relationship
between behavioral intention and attitude, subjective norms, and perceived behavioral
control. A +1 and -1 indicates a strong correlation between variables and 0 indicates no
effect. (Morgan, 2013). Using Cohen’s guidelines to the interpretation of relationship
strength, absolute r values less than 0.1 are considered small, absolute r values 0.3>r>0.1
are considered moderate or medium, and absolute values 0.5>r>0.3 are considered larger
(Morgan, 2013).
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CHAPTER FOUR: RESULTS
A total of 160 online surveys (12% response rate) were captured during the
collection period with a 68% completion rate. Cases were eliminated from data analysis if
less than 65% of the survey was complete. Cases were also excluded if participants
indicated they were retired, not practicing, or if practice setting did not align with the
study (e.g. specialty home infusion, long-term care facility, pharmaceutical company). As
a result, 52 cases did not meet the criteria and were eliminated from the analysis.
Specifically, 42 cases withdrew participation in the early demographics stages of the
questionnaire and 10 cases were either retired, not working, or excluded due to practice
setting. In total, 108 cases were used in analysis.
The descriptive statistics on the demographic data are presented in Table 4.1.
Female participants represented 53.3% of the sample with 46.7% of male respondents.
Participants ages ranged from 26 years old to 72 years old (M= 47.8). The majority of
participants held a doctoral-level degree (80.4%) and there was a wide range in number
of years practicing pharmacy. In regards to practice setting, 36.1% of participants
indicated currently working in a drug or grocery store pharmacy, and the second-highest
category in practice setting was a health system pharmacy at 22.2%. When asked about
the number of opioid prescriptions they filled each week, 18% indicated zero. However,
63% of participants filled anywhere between 1-100 opioid prescriptions in a week with 3
participants indicating they fill over 400. When asked about approximate hours of
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continuing education related to opioid use disorders, the majority (65.4%) responded
between 1 and 10 hours of education.

28
Table 4.1

Pilot study participant demographic characteristics
Characteristic

Frequency

Percentage (%)

Total N

50
57

46.7
53.3

107
107

25
30
23
17
9

24
28.8
22.1
16.3
8.7

104
104
104
104
104

21
11
9
10
38
15

20.2
10.6
8.6
9.6
36.6
14.4

104
104
104
104
104
104

14
10
13
16
14
16
6
14

13.6
9.7
12.6
15.5
13.6
15.5
5.9
13.6

103
103
103
103
103
103
103
103

39
19
14
12
24

36.1
17.6
13.0
11.1
22.2

108
108
108
108
108

13
8
12
37
13
13
11

12.1
7.5
11.2
34.6
12.1
12.1
10.3

107
107
107
107
107
107
107

19
2
86

17.8
1.9
80.4

107
107
107

Sex
Male
Female
Age (mean= 47.8, median=47)
26-35
36-45
46-55
56-65
>65
Hours per week working in a
community pharmacy setting
0
1-10
11-20
21-30
31-40
>40
Years practicing pharmacy
1-3
4-6
7-10
11-15
16-20
21-25
26-30
>30
Primary Practice Setting
Grocery or drug store
Independent Pharmacy
Mass Merchandiser
Outpatient/Clinic
Health System Pharmacy
Idaho Public Health District
PHD 1
PHD 2
PHD 3
PHD 4
PHD 5
PHD 6
PHD 7
Education
Bachelor
Master
PharmD
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Number of year since completing
highest degree
1-5
6-10
11-15
16-20
21-30
31-40
>40
Approximate number of Continuing
Education hours completed for
Opioid Use disorder
>1
1-5
6-10
11-15
16-20
21-30
31-40
>40
Avg. Opioid prescription filled in a
week
0
1-50
51-100
101-200
201-300
300-400
>400

23
16
15
15
22
9
6

21.7
15.1
14.1
14.1
20.8
8.5
5.7

106
106
106
106
106
106
106

2
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25
11
11
4
3
4

2
40.6
24.8
10.9
10.9
3.9
3
3.9

101
101
101
101
101
101
101
101

18
40
23
9
4
3
3

18
40
23
9
4
3
3

100
100
100
100
100
100
100

Factor Analysis
As previously discussed in the methodology section, this study used the
Exploratory Factor Analysis (EFA) to examine the factor structures of the survey tool. An
EFA was conducted on the 48 items based on the five Theory of Planned Behavior
constructs with non-orthogonal rotation (Direct Oblimin). To determine how many
factors to extract, a combination of criteria was created: (a) the number of constructs and
subconstructs in the Theory of Planned Behavior, (b) eigenvalues-greater-than-1 for each
factor, (c) the scree test, and (d) interpreting item loading factors extracted.
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Attitude
The Kaiser-Meyer-Olkin (KMO) measure verified the sampling adequacy for the
analysis, KMO = 0.733 (sufficient items for each factor should be 0.70 or greater and
adequate items at 0.50) (Morgan, 2013). Bartlett’s test of sphericity x2 = 485.058, df =
36, p = <0.000, indicating that correlations between items were sufficiently large for
PCA. Two components had eigenvalues over Kaiser’s criterion of 1 and in combination
explained 64.5% of the variance as shown in Table 4.2. The scree plot, however, showed
flattening after the third factor, suggesting that a third factor might be interpretable
(Figure 4.1).
Table 4.2
Extraction

Total Variance Explained for Attitude: Factor Solution with PCA
Initial Eigenvalues

Factor
1
2
3

Total
3.825
1.978
0.874

% of Variance
42.497
21.975
9.711

Cumulative %
42.497
64.472
74.183

Rotation Sums of Squared
Loadings
Total
3.257
2.852
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Figure 4.1

Nine item screen plot for Attitude

The next step was to explore the rotated structure matrix of the two-factor
solution. Table 4.3 shows the factor loadings after rotation using a structure matrix. The
items cluster on the same components suggest that items A13 through A16 load onto
factor one. Items that loaded onto factor one asked participants questions such as
Q14.1“when the validity of an opioid prescription is in question, I believe it would be
useful to screen patients for misuse,” and Q15 “I believe it is a pharmacist’s professional
duty to briefly intervene with feedback and advice when patients show risky prescription
opioid use.” Items that loaded onto the second factor included questions such as Q17
“Overall, prescribers are more responsible than pharmacists for screening patients for
prescription opioid misuse,” and Q19 “Overall, prescribers are more responsible than
pharmacists for referring patients to treatment for prescription opioid misuse.”
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Items A15 and A16 were originally intended to load onto factor two and capture
values attached to the outcome. However, factor loadings indicate items cluster with
factor one. Item A16 appears to cross-load on both factors above |0.40|.
Table 4.3

Attitude factor loadings after rotation
Item
A13
A14.1
A14.2
A14.3
A15
A16
A17
A18
A19

Factor Loadings
1
2
.052
.464
-.217
.839
-.316
.846
.102
.592
.-339
.852
-.438
.669
-.255
.901
-.087
.885
-.158
.890

Subjective Norms
The KMO measure for the 18 subjective norms items verified the sampling
adequacy (KMO = 0.778) and Bartlett’s test of sphericity x2 = 1931.633, df = 153, p =
0.000 indicated factor analysis would be useful. As presented in Table 4.4, five
components had eigenvalues greater than 1, and the combination explained 82.0% of the
variance. Factors six and seven were also close to 1, and the scree plot in Figure 4.2
revealed ambiguous flattening between the fourth and eighth components.
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Table 4.4
Total Variance Explained for Subjective Norms: Factor Solution with
PCA Extraction
Initial Eigenvalues
Factor
1
2
3
4
5
6
7

Total
6.944
3.352
2.015
1.320
1.128
0.973
0.679

Figure 4.2

% of Variance
38.578
18.631
11.192
7.333
6.266
5.408
3.770

Cumulative %
38.578
57.199
68.391
75.724
81.990
87.398
91.168

Rotation Sums of
Squared Loadings
Total
4.797
4.269
4.007
4.425
4.396

Eighteen-item scree plot for Subjective Norms

However, the TPB Subjective Norms should reflect two underlying latent
variables: normative belief and motivation to comply. Based on the theoretical model,
subjective norms were forced to two factors which then explain 57.2% of the variance.
Table 4.5 shows the factor loadings after rotation using a structure matrix and suggest
that the items in subjective norms work well with two factors. Items that cluster onto

34
factor one reflect respondents’ motivation to comply with what their supervisor and other
pharmacists want. Factor one questions include items like Q21.1 “when it comes to
screening patients for prescription opioid misuse, I want to do what my supervisor thinks
I should do.” Items S25.1-25.3 asking about motivation to comply concerning friends and
family correlate strongly to both factors above |0.40|. Items that cluster onto factor two
ask questions such as Q25.2 “how much do you agree that your friends and family think
you should briefly intervene with feedback and advice about opioid misuse?” The items
that cluster onto factor one appear to represent motivation to comply and factor two
represents normative belief in subjective norms.
Table 4.5

Subjective Norms factor loadings force to 2 after rotation
Item
S20.1
S20.2
S20.3
S21.1
S21.2
S21.3
S22.1
S22.2
S22.3
S23.1
S23.2
S23.3
S24.1
S24.2
S24.3
S25.1
S25.2
S25.3

Factor Loadings
1
2
.054
.712
-.098
.715
.076
.689
.143
.725
.332
.791
.215
.738
.096
.714
.197
.766
.295
.811
.112
.719
.176
.781
.292
.800
.264
.772
.235
.774
.337
.727
.503
.643
.444
.730
.421
.679

Perceived Behavioral Control
The KMO measure for the nine items in Perceived behavioral control (PBC)
indicated acceptable sampling with a KMO = 0.636, and Bartlett’s Test of Sphericity x2 =
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371.160, df = 36, p = 0.000. Initial analysis showing eigenvalues over 1 indicated three
interpretable factors for PBC as shown in Table 4.6 and was supported by the scree plot
in Figure 4.3. The three items that loaded onto factor one included “For me, questioning a
patient with whom I have a relationship with would be easy,” and “…engaging patients
in a discussion relating to prescription opioid misuse would be easy for me.” Factor two
included items regarding the decision to screen, briefly intervene, and refer to treatment
being beyond the participant’s control. Finally, the third factor appeared to relate to
confidence in their ability to perform each behavior.
Table 4.6
Extraction

Total Variance Explained for PBC: Factor Solution with PCA
Initial Eigenvalues

Factor
1
2
3

Total
2.959
2.235
1.138

% of Variance
32.879
24.830
12.640

Figure 4.3

Cumulative %
32.879
57.710
70.350

Rotation Sums of Squared
Loadings
Total
2.383
2.361
2.208

Nine-item scree plot for PBC
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The next step was to explore the rotated structure matrix of the factor solution.
Table 4.7 shows the factor loadings after rotation using a structure matrix. When the
factor analysis was forced to two factors to align with the TPB PBC constructs, the
“easy” items P26, 29-30 and “confidence” items P28.1-28.3 loaded onto factor one while
the control items loaded onto factor two. The two factors explained 57.7% of the variance
as seen in Table 4.6. The items that cluster on factor one appear to represent perceived
power, which measures the perceived effect of making behavioral performance difficult
or easy. Factor two represents control belief in PBC which measures the perceived
likelihood of occurrence of each facilitating or constraining condition.
Table 4.7

PBC factor loadings force to 2 after rotation
Item
P26
P27.1
P27.2
P27.3
P28.1
P28.2
P28.3
P29
P30

Factor Loadings
1
2
-.106
.731
-.092
.883
-.095
.922
-.117
.832
-.019
.760
-.005
.815
-.054
.567
-.136
.561
-.127
.662

Behavioral Intention
Behavioral intention KMO measure verified acceptable sampling for the analysis,
KMO = .639 and Bartlett’s Test of Sphericity x2 = 314.094, df = 15, p = 0.000 for the six
items. Initial factor analysis indicated items load onto two factors shown by the
eigenvalues over 1 in Table 4.8, and the “elbow” in the scree plot in Figure 4.4 also
indicates two factors.
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Table 4.8
Total Variance Explained for Behavioral Intention: Two-Factor
Solution with PCA Extraction
Initial Eigenvalues
Factor
1
2

Total
3.294
1.039

Figure 4.4

% of Variance
54.897
17.316

Cumulative %
54.897
72.213

Rotation Sums of Squared
Loadings
Total
2.689
2.649

Six items scree plot for Behavioral Intention

However, when exploring the rotated structure of the two-factor solution five of
the six items load highly (above |0.40|) onto both factors as shown in Table 4.9. The
underlying TBP behavioral intention also does not have an underlying subscale and
therefore BI was forced to one factor.
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Table 4.9

Behavioral Intention Factor Loadings
Item
B33
B34
B35
B36.1
B36.2
B36.3

Factor Loadings
1
2
.442
-.924
.377
-.935
.532
-.554
.764
-.499
.797
-.558
.922
-.230

Past Behavior
Lastly, a principal component analysis was conducted on the six items for past
behavior. The KMO measured indicated an acceptable sampling for the analysis (KMO =
0.587) and Bartlett’s Test of Sphericity x2 = 101.446, df = 15, p = 0.000. Similar to
behavioral intention, initial analysis indicated items load onto two factors for past
behavior as shown in Table 4.10 and by the scree plot in Figure 4.5. However, the TPB
past behavior should demonstrate one factor in the model, but does ask about ever
performing the behavior and performing in the past 30 days. The rotated factor structure
in Table 4.11 shows items PB31.3 and PB32.3 asking about past behavior performing
referral to treatment load onto the second factor. To align with the theoretical model, past
behavior was forced into one factor, which explains 37.6% of the variance.
Table 4.10
Total Variance Explained for Past Behavior: Factor Solution with
PCA Extraction
Initial Eigenvalues
Factor
1
2

Total
2.256
1.146

% of Variance
37.595
19.098

Cumulative %
37.595
56.693

Rotation Sums of Squared
Loadings
Total
2.034
1.609
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Figure 4.5

Table 4.11

Past Behavior Scree plot for six item

Past Behavior Factor Loadings
Item
PB31.1
PB31.2
PB31.3
PB32.1
PB32.2
PB32.3

Factor Loadings
1
2
.259
.754
.322
.703
.242
.802
-.076
.668
.259
.650
.211
.850

Reliability
Based on the factor analysis of the 48 items, eight factors were derived.
Cronbach’s alpha tests were computed to determine if the factor subscales were reliable.
Cronbach’s alpha tests supported findings from the factor analysis, and overall, data
indicated strong internal subscale consistency except for past behavior. The subscale
alpha scores were determined as follows: attitude behavioral belief (questions A13-16; α
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= 0.816), attitude evaluation (A17-19; α = 0.885), subjective norms normative belief
(S20, S24; α = 0.859), subjective norms motivation to comply (S21-23; α = 0.911),
perceived behavioral control; control belief (P27; α = 0.853), perceived behavioral
control perceived power (P26, P28-30; α = 0.762), behavioral intention (BI33-36; α =
0.830), and past behavior (PB31-32; α = 0.661). Scores 0.80 and above indicated good
internal consistency reliability, while scores 0.60 and above indicate adequate
consistency. Overall, the data illustrated strong internal reliability on seven of the eight
subscales.
Correlation
Pearson correlations were computed on each of the TPB subscales that appeared
through factor analysis. The correlation was used to examine the relationships between
the subscales and can be found in Table 4.12. The first column shows the correlations of
other variables with attitude behavioral belief (factor 1), the second column shows the
correlation of other variables with attitude evaluation (factor 2), and so on. Overall,
positive correlations were found between behavioral intention and the other TPB
constructs. Six out of the seven variables in the TPB model to determine behavioral
intention are significantly correlated to behavioral intention. Attitude behavioral belief
(.693), subjective norms normative belief (.571), perceived behavioral control perceived
power (.550), and past behavior (.649) all have a large relationship with behavioral
intention based on Cohen’s guidelines outlined in the Methods section. Attitude
evaluation (-.265) and perceived behavioral control control belief (-.238) have a medium
relationship while subjective norms motivation to comply (.161) shows to have a weak
relationship.
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Table 4.12

Subscale Bivariate Correlation

Factor
1
2
3
4
5
Attitude
1
Behavioral
Belief
Attitude
-.274**
1
Responsibility
Motivation to
.094
.046
1
comply
Normative
.602**
-.103
.259**
1
Beliefs
Control Belief -.266** .454**
.003
-.123
1
Perceived
.339**
-.071
.019
.228*
-.125
Power
Past Behavior .402**
.032
.124 .396** -.036
Intention
.161 .571** -.238*
.693** -.265**
**Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).

6

7

8

1
.649**

1

1
.491**
.550**
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CHAPTER FIVE: DISCUSSION
The primary goal of this study was to adapt a TPB-based instrument to measure
pharmacists’ perceptions toward using SBIRT and to test initial reliability and validity.
These results offer a foundation for future research to build on the instrument and inform
pharmacist readiness in prescription misuse early intervention strategies. This chapter
summarizes the findings from the factor analysis of the 48-items for the TPB and
implications for exploring an SBIRT pilot in an Idaho pharmacy setting. Limitations of
this study as well as suggestions for future research are also addressed in this chapter.
Defining and Refining Underlying Factor Structure
Factor analysis of the theory of planned behavior constructs in the instrument
supported the eight-factor solution that was conceptually hypothesized. As mentioned in
Chapter 3, items were retained if it loaded onto a factor with an absolute value of 0.40 or
more and shared a conceptual meaning.
Attitude
In the Theory of Planned Behavior, the construct attitude is determined by two
underlying themes: behavioral beliefs and evaluation. Behavioral belief captures if
SBIRT performance is associated with certain attributes or outcomes while evaluation
aims to capture values attached to the behavioral outcome (Glanz et al., 1996). Under
attitude, six items loaded onto factor one above |0.40| and were developed to characterize
behavioral beliefs. Three items loaded onto factor two above |0.80| but appeared to
represent who is responsible to screen and intervene more so than the sub-construct
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evaluation, which was the original intended latent construct for those items. Factor one
items included A13 that captured beliefs if prescription opioid misuse was a problem in
their community, A14.1-14.3 that captured if using SBIRT behaviors “…would be useful
to use in cases of prescription opioid misuse,” and A15-16 that captured if pharmacists
considered SBI a professional duty. These items capture if pharmacists consider opioid
misuse a problem in their community, if they consider screening and intervening a
professional duty, and if they believe it would be useful to use SBIRT in instances where
misuse is suspected. Combined, these items appear to measure more than just behavioral
beliefs and could measure a more general attitude towards SBIRT and if misuse is a
problem in their community.
Three items under attitude loaded onto a second factor well over the established
benchmark of |0.40|. The evaluation subtheme in attitude was intended to be measured by
instrument items A15-19 to capture if values of professional duty and responsibility
would motivate pharmacists to use SBIRT. However, after analysis, it appears items
A17-19 appear to capture pharmacists’ perception towards who is more responsible in
early intervention strategies, which is not a TPB construct in attitude. Therefore, with the
items A15-16 loading onto factor one, and the content in items A17-19, the subscales
were labeled “attitude” and “responsibility” rather than “behavioral belief” and
“evaluation” as outlined in the model.
Subjective Norms
The TPB notes that normative beliefs and motivation to comply make up the
construct subjective norms. Normative beliefs capture perceptions towards whether each
referent approves or disapproves of the behaviors while motivation to comply captures
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the motivation to do what each referent thinks (Glanz et al., 1996). In subjective norms,
nine items loaded onto factor one above |0.70| and appeared to represent motivation to
comply while six items loaded onto factor two above |0.60| for normative belief. Without
being forced into two factors, analysis revealed ambiguous factor loadings for subjective
norms with 5-6 interpretable factors. This could mean that pharmacists consider the
approval of their supervisor, other pharmacists, and friends/family differently and are
motivated to comply with what each referent thinks differently. For example, factor one
clustered together for normative beliefs for supervisors and other pharmacists, which
aligns well with the TPB. However, factor two hangs together for motivation to comply
with other pharmacists, while factor three hangs together for motivation to comply with
supervisors. This could mean that pharmacists are motivated differently by their
supervisors compared to other pharmacists. Additionally, factor four captures motivation
to comply with friends and family and factor five captures normative beliefs for friends
and family.
To represent the theory, subjective norms were forced to two factors and
explained 57.2% of the variance in the overall construct. When forced to two factors,
motivation to comply with each of the three referents clustered onto factor one as
originally intended to follow the theory. Items that capture normative beliefs for other
pharmacists and supervisors again clustered onto the same factor as predicted in the TPB
model. However, item S25.1-25.3 that captures whether respondents believe friends and
family think they should use SBIRT revealed to hang on both factors. It is common for
items to cross-load onto factors, but the three items loaded onto motivation to comply and
normative beliefs at nearly the same level. This variance from the TPB is potentially due
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to poor measurement, or that pharmacists answered the items in a similar way between
normative beliefs and motivation to comply with friends or family. It could also mean
that, to pharmacists, it does not matter what friends and family approve or disapprove of
in the workplace. Items S25.1-25.3 were eliminated from the instrument because of
ambiguous factor loadings. The themes that emerged in subjective norms were labeled
“motivation to comply” and “subjective norms” because they reflected the underlying
subconstructs in the TPB model.
Research also indicates that, regarding subjective norms, pharmacists’ normative
behavior may also be shaped by insurance companies and the provider-pharmacist
relationships, potentially more so than friends or family (Fleming et al., 2019; Hagemeier
et al., 2014). Pharmacists may also be influenced by regulatory entities such as the Board
of Pharmacy or the Drug Enforcement Administration. These referents were not included
in the instrument items in this study.
Perceived Behavioral Control
Perceived behavioral control (PCB) is also made up of two underlying constructs:
perceived power and control belief. According to the TPB, perceived power aims to
capture the perceived effect of a condition that makes performing the behavior easy or
difficult, and control aims to capture the likelihood of the occurrence of each facilitating
or constraining condition (Glanz et al., 1996). Initial analysis of PBC revealed three
interpretable factor structures that appeared to measure ease of performing the behavior,
confidence, and control. Since the construct of perceived behavioral control should
measure (1) the ease of performing the behavior and (2) whether or not it is within the
respondent’s control, the third interpretable factor could capture self-efficacy (confidence
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to carry out behavior). Yet, when forced to two factors the two PBC subthemes emerged.
The PBC construct was left at two factors because items P28 that emerged as the third
interpretable factor for self-efficacy could also be considered a condition that makes
behavioral performance difficult or easy. An example of this would be low confidence in
referring a patient to treatment that would make performing the behavior more difficult.
Additionally, P29 asks pharmacists whether having a relationship with the patient would
make engaging patients in a discussion about prescription opioid misuse easy. The item
asks if a relationship with the patient makes engaging the patient easier or more difficult,
which aligns with the perceived power subtheme that captures the perceived effect of
conditions that make behavioral perform easy or difficult. The two subscales in PBC
were then labeled “perceived power” and “control belief” from the TPB conceptual
model.
Behavioral Intention and Past Behavior
The analysis of behavioral intention, which captures the perceived likelihood of
performing the behavior, and past behavior showed four interpretable factors based on
the eigenvalues and scree plots. The two themes in behavioral intention appeared to
delineate wanting to perform the behavior and intending to perform the behavior. This
finding may reflect discrepancies in wanting to intervene in prescription misuse but
pharmacists may not have the perceived behavioral control to do so. However, five of the
six items in behavioral intention cross-loaded onto the two factors above |0.4|. In the TPB
model, behavioral intention is a single outcome that is influenced by attitude, subjective
norms, and perceived behavioral control. Due to the items cross-loading and following
the theoretical model, behavioral intention was left at one factor.
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Similarly, the six items in past behavior revealed two factors. Factor one appeared
to delineate past the 30 days and ever performing SBI while factor two captured the past
30 days and ever performing referral to treatment. The emergence of two factors is not
surprising considering SBIRT is not currently used in a pharmacy setting and therefore
past behavior will not be consistent across respondents. Previous studies also revealed
that, although SBIRT is not systemically implemented in pharmacies, some pharmacists
still appear to occasionally screen, briefly intervene, and/or refer a patient to treatment
(Cochran et al., 2014; Hagemeier et al., 2014). Past behavior alpha scores were also
lower than the other constructs due to variation in past experiences across the three
behaviors. Similar to behavioral intention, past behavior was forced and left at one factor
to follow the TPB model and because this factor measures past performances of the
behavior and not a belief or attitude towards performing it.
Across all behaviors, the reliability was supported by the internal consistency
values for each construct that is reflected in high Cronbach’s coefficient alphas.
One interesting finding of this study is that referral to treatment questions emerged
differently in analysis than screening and brief intervention, particularly in behavioral
intention and past behavior. This may suggest that pharmacists’ willingness to actively
engage in SUD intervention is different than more passive behaviors like SBI. This
concept has also been suggested by previous research that indicated pharmacists’ selfefficacy in discussing treatment facility information with patients is low (Hagemeier et
al., 2014). Furthermore, pharmacists appear more cautious making the leap from just
screening and engaging in a discussion to all three SBIRT behaviors (Riley & Alemagno,
2019).
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Lastly, practice setting is supported in the research in potentially influencing
perceptions, behavioral performance, and barriers to providing SBIRT in a pharmacy
setting (Cochran et al., 2015). Therefore, the demographics questions capturing education
level, age, gender, practice setting, and amount of education about this topic remained in
the tool. Furthermore, when administering a TPB-based questionnaire, items from each
construct should be presented in a non-systemic order rather than by construct like what
was done in the pilot instrument.
Correlation
The Theory of Planned Behavior posits that the more favorable attitude and
subjective norms and the higher perceived behavioral control are the stronger a person
intends to perform the behavior. The Pearson correlation was used to test initial
relationships between TPB constructs measured in the instrument and behavioral
intention to determine if the items align with the model. The correlation showed
significant relationships at 0.01 between behavioral intention and attitude, attitude
responsibility, subjective norms normative beliefs, perceived behavioral control
perceived power, and past behavior. There was also a significant relationship at the 0.05
level between behavioral intention and perceived behavioral control control belief, but
there was no significant relationship between motivations to comply and intention. The
motivation to comply subconstruct hangs together well in factor analysis and shows high
internal consistency, however it does not have a large influence on behavioral intention or
even past behavior. Motivation to comply also does affect any of the constructs (except
normative beliefs) or outcomes, which may indicate that it does not have an effect on
pharmacists using SBIRT. This could also be due to how the questions were written or, as
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mentioned above, was looking at the wrong referents. The previous study used to adapt
items asked about “most people who are important to me” and “other pharmacists” for
motivation to comply. These items were split between referents believed to influence
participants: friends/family, other pharmacists, and supervisors.
Limitations
Limitations of this study include sampling issues. To begin, the distribution list of
pharmacists still captured participants working in a hospital. If participants were currently
practicing, their responses were left in psychometric testing to maintain an adequate
number of responses needed for tests because of the small sample size. Secondly, there
was a low response rate. The low response rate could be due to several reasons including
fatigue in discussing prescription opioid misuse or responding to opioid-related surveys.
There is also a possibility that pharmacists are tired of responding to surveys because of
numerous email invitations received to participate in studies. Additionally, the email
distribution was sent from a Boise State University address and participants may be more
likely to respond had it come from a pharmacy association, the Board of Pharmacy, or the
College of Pharmacy at Idaho State University.
Another limitation of this study is adapting the survey items from a previous tool
rather than eliciting salient beliefs about the combined SBIRT behaviors before survey
development. Although the questions were derived from the TPB tool on utilizing the
prescription monitoring program, which could be considered the first step in screening
for misuse, the perceptions toward brief intervention and referral to treatment could be
much different. The nature of the self-report survey instrument is another limitation in
this study. Some caution should be given when using self-report measures when testing
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reliability and validity. Using multiple methods such as interviews or focus groups in
addition to self-report would provide more measures to ensure validity and reliability.
Finally, another limitation in this study could be practicing pharmacists’ general
understanding of what SBIRT is since they are not typically trained in SBIRT or use it in
daily practice. The SAMHSA SBIRT definitions were provided in the survey, however,
the interpretation of a universal screening or brief intervention could vary in participants.
Suggestions for Future Research
Future research could take numerous directions following this study. This study
developed one of the first TPB-based instruments that look at pharmacists’ perceptions
toward all three SBIRT behaviors for prescription misuse. The results from this study
suggest future research is needed to continue testing the validity and reliability of the
tool, such as conducting test-retest reliability or conducting a Confirmatory Factor
Analysis to test the TPB. There is also a need to take an in-depth look into the subscales
that varied from the TPB model, such as subjective norms and attitude. For example, a
deeper dive into motivation to comply and normative beliefs is needed to determine if the
referents chosen have the most impactful influence on pharmacists’ workplace decisions.
A previous study by Fleming et al. (2019) gathered pharmacists’ salient normative beliefs
towards their willingness to engage patients in a discussion and then refer indicated
prescribing physicians as an influential referent in their decision. Other referents that
appeared were regulatory agencies like the DEA or pharmacy boards, employers in
addition to direct supervisors, and possibly patients. In previous research, pharmacists
who felt they had a right to ask about misuse were twice as likely to engage patients in a
discussion about it (Cochran et al., 2015). Pharmacists who felt their patients believed the
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pharmacists had a right to ask were 88% more likely to discuss misuse. Considering the
limitations in the self-report measures, future studies may also consider using other
measures to investigate perceptions toward implementing SBIRT. Examples could
include qualitative measures such as focus groups or interviews, or piloting the model to
gain a more comprehensive understanding.
Future research should also consider the difference in perceptions for
implementing SBI and referral to treatment. Initial analysis showed that attitude,
subjective norms, and perceived behavioral control toward referral to treatment may be
different from screening and brief intervention. This is supported in the research that
patients and pharmacists alike are more apprehensive toward referral to treatment for
substance use than the other behaviors (Riley & Alemango, 2018). Some research
indicates this could be mitigated by more dissemination of prescription opioid-specific
continuing education, improving self-efficacy beliefs, and dissemination of addiction
treatment information (Hagemeier et al., 2014). Finally, this instrument only focused on
early intervention for prescription opioid misuse. However, future studies may want to
consider examining other commonly misused controlled substances such as
benzodiazepines or sedatives.
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Pharmacists’ Perceptions Toward Prescription Opioid Misuse: Development of a
valid and reliable survey questionnaire
From: Boise State University, College of Health Sciences
Subject line: Invitation: Participate in Idaho Pharmacy Survey
Feedback Requested: Idaho Pharmacy Survey
Good morning,
A graduate student at Boise State University is conducting a pilot research study designed
to develop a valid and reliable survey questionnaire. The purpose of this pilot study is to
explore Idaho pharmacists’ perceptions toward screening patients for prescription opioid
misuse, briefly intervening with feedback and advice, and referring patients to treatment
if needed.
Your responses are voluntary and will be kept confidential. This survey should take
approximately 15-20 minutes to complete. You must be a pharmacist who is currently
practicing in the state of Idaho. We appreciate your response by April 18, 2019.
If you consent to participate, please complete the following survey.

If you have any questions regarding the survey or its purpose, please send inquiries to:
Tara Fouts
Community & Environmental Health
tarafouts@u.boisestate.edu

Dr. Sarah Toevs
Community & Environmental Health
stoevs@boisestate.edu

If you have questions about your rights as a research participant, you may contact the
Boise State University Institutional Review Board (IRB), which is concerned with the
protection of volunteers in research projects. You may reach the board office between
8:00 AM and 5:00 PM, Monday through Friday, by calling (208) 426-5401 or by writing:
Institutional Review Board, Office of Research Compliance, Boise State University, 1910
University Dr., Boise, ID 83725-1138.
We appreciate your participation in this survey.
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Construct

Behavior 1
Screen patients for
risky substance use
behaviors

Behavior 2
Engage patients in a
short discussion
about substance
misuse and opioid
use disorder (OUD)

Behavior 3
Referral to
Treatment

Attitude
Q13 Prescription
opioid misuse is a
problem in my
community.
Q14.1 When the
Behavioral
validity of an opioid
Belief:
prescription is in
Belief that
question, I believe it
behavioral
would be useful for
performance is
a pharmacist to:
associated with
certain attributes screen patients for
prescription opioid
or outcomes
misuse.
Q15 I believe it is a
Evaluation:
pharmacist’s
Value attached
professional duty to
to a behavioral
screen patients for
outcome or
prescription opioid
attribute
misuse.

Q17 Overall,
prescribers are more
responsible than
pharmacists are to
engage patients in a
short discussion
about prescription
opioid abuse and
misuse.
Subjective Norms
Q20.1 Considering
Normative
pharmacists whose
Belief: Belief
opinions you value,
about whether
to what extent do
each referent
you agree they
approves or
would: screen
disapproves of
patients for
the behavior

Q14.2 When the
validity of an opioid
prescription is in
question, I believe it
would be useful for a
pharmacist to:
briefly intervene by
providing feedback
and advice.
Q16 I believe it is a
pharmacist’s
professional duty to
briefly intervene
with feedback and
advice when patients
show risky
prescription opioid
use.
Q18 Overall,
prescribers are more
responsible than
pharmacists are to
screen for
prescription opioid
abuse and misuse.

Q14.3 When the
validity of an opioid
prescription is in
question, I believe it
would be useful for
a pharmacist to:
advise patients to
consult their
prescriber

Q20.2 Considering
pharmacists whose
opinions you values,
to what extent do
you agree they
would: briefly
intervene with

Q20.3 Considering
pharmacists whose
opinions you values,
to what extent do
you agree they
would: refer patients

Q19 Overall,
prescribers are more
responsible than
pharmacists are to
refer to treatment for
prescription opioid
misuse and abuse.
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prescription opioid
misuse?
Q24.1 How much
do you agree that
your supervisor
thinks you should
screen patients for
prescription opioid
misuse?
Motivation to
comply:
Motivation to do
what each
referent thinks

Q21.1 When it
comes to screening
patients for
prescription opioid
misuse, I want to do
what my supervisor
thinks I should do.
Q21.2 I want to do
what other
pharmacists who
opinions I value
think I should do
Q21.3 I want to do
what my
friends/family think
I should do

Perceived Behavioral Control
Q27.1 The decision
Control belief:
to screen patients for
Perceived
prescription opioid
likelihood of
misuse is beyond
occurrence of
each facilitating my control.
or constraining
condition
Perceived
power:
Perceived effect
of each condition
in making
behavioral
performance
difficult or easy
Q28.1 I am
confident in my

feedback and advice
about opioid misuse?
Q24.2 How much do
you agree that your
supervisor thinks
you should briefly
intervene with
feedback and advice
about prescription
opioid misuse?
Q22.1 When it
comes to providing
patients feedback
and advice about
prescription opioid
misuse, I want to do
what my supervisor
thinks I should do
Q22.2 I want to do
what my
friends/family think
I should do

to treatment
resources if needed?
Q24.3 How much do
you agree that your
supervisor thinks
you should refer a
patient to treatment
if needed.

Q22.3 I want to do
what other
pharmacists whose
opinions I value
think I should do

Q23.3 I want to do
what other
pharmacists whose
opinions I value
think I should do

Q27.2 The decision
to briefly intervene
with feedback and
advice is beyond my
control.

Q27.3 The decision
to refer patients to
treatment is beyond
my control.

Q23.1 When it
comes to referring
patients to additional
treatment resources,
I want to do what
my supervisor thinks
I should do.
Q23.2 I want to do
what my
friends/family think
I should do.

Q26 How much do
you agree with this
statement: Engaging
patients in a
discussion relating to
prescription opioid
misuse would be
easy for me.
Q28.2 I am
Q28.3 I am
confident in my
confident in my
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ability to screen
patients for
prescription opioid
misuse

ability to briefly
intervene with
feedback and advice

ability to refer a
patient to treatment
if needed.

Q29 For me,
questioning a patient
with whom I have a
relationship with
about the legitimacy
of a PO would be
easy/difficult
Q30 For me,
questioning a patient
with whom I have
no strong
relationship with
about the legitimacy
of a PO would be
easy/difficult
Past Behavior
Q31.1 In the past 30
days, have you
screened a patient
for prescription
opioid misuse?
Q32.1 In your
pharmacy practice,
have you ever
screened a patient
for prescription
opioid misuse?
Behavioral Intention
Q33 How much, if
Perceived
any, do you intend
likelihood of
to screen patients for
performing the
prescription opioid
behavior
misuse?

Q36.1 I want to
screen patients for
prescription opioid
misuse

Q31.2 In the past 30
days, have you
Briefly intervened
with feedback and
advice?
Q32.2 In your
pharmacy practice,
have you ever
briefly intervened
with feedback and
advice?

Q31.3 In the past 30
days, have you
Referred a patient to
additional treatment
resources?
Q32.3 In your
pharmacy practice,
have you ever
referred a patient to
additional treatment
resources?

Q34 How much, if
any, do you intend to
briefly intervene
with feedback and
advice for
prescription opioid
misuse?
Q36.2 I want to
briefly intervene
with feedback and
advice for
prescription opioid
misuse

Q35 How much, if
any, do you intend to
refer patients to
additional treatment
resources if needed?

Q36.3 I want to refer
patients to additional
resources if they
need it.
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APPENDIX D
Piloted Instrument
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Q1 Do you currently provide patient care in a community pharmacy setting?
___Yes
___No
Q2 On average, how many hours per week do you work in a community pharmacy?
Q3 Approximately how many years have you been practicing pharmacy?
Q4 What best describes your primary practice site?
___Grocery or drug store chain (i.e. Sav-on, Rite-Aid)
___Independent pharmacy
___Mass merchandiser (i.e. Walmart)
___Outpatient/clinic pharmacy
___Health system pharmacy
___Other (please specify)
Q5 Please select the Idaho county in which you primarily practice.
▼ Ada ... Washington
Q6 Please indicate your highest level of education completed.
___Bachelor
___Master
___PharmD
___Other (please specify)
Q7 What year did you graduate with your highest pharmacy degree?
Q8 Since graduation, approximately how many Continuing Education training hours have
you completed for opioid use disorder?
Q9 On average, how many opioid prescriptions do you fill in a week?
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Q10 Please indicate your sex.
___Male
___Female
___Other (please specify)
Q11 What year were you born?
Q12 Please consider your community pharmacy practice and the definitions below when
answering the following questions.
Prescription opioid misuse: using a prescription in a manner other than directed by a
doctor including using in greater amounts than prescribed, more often, or for longer
periods than instructed.
Screening: a healthcare professional assessing a patient for risky substance use behavior
using a standardized screening tool.
Brief intervention: engaging a patient showing risky substance use behaviors in a short
conversation providing feedback and advice. Depending on the severity or risk for
adverse consequences, a 5-10 minute discussion or longer 20-30 minute discussion
provides the patient with personalized feedback showing concern over prescription use.
Referral to treatment: providing a referral to brief therapy or additional treatment to
those who screen in need of additional services.
Q13. How much do you agree with this statement: Prescription opioid misuse is a
problem in my community.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q14. When the validity of an opioid prescription is in question, I believe it would be
useful for a pharmacist to:

Strongly
agree

Agree

Somewhat
agree

Neither
agree
nor
disagree

Somewhat
disagree

Disagree

Strongly
disagree

Screen
patients for
prescription
opioid
misuse

O

O

O

O

O

O

O

Briefly
intervene by
providing
feedback
and advice

O

O

O

O

O

O

O

Advise
patients to
consult their
prescriber

O

O

O

O

O

O

O

Q15 I believe it is a pharmacist's professional duty to screen patients for prescription
opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q16 I believe it is a pharmacist's professional duty to briefly intervene with feedback and
advice when patients show risky prescription opioid use.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q17 Overall, prescribers are more responsible than pharmacists are for screening patients
for prescription opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q18 Overall, prescribers are more responsible than pharmacists are for briefly
intervening with feedback and advice on prescription opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q19 Overall, prescribers are more responsible than pharmacists are for referring people
to treatment for prescription opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q20 Considering pharmacists whose opinions you value, to what extent do you agree
they would:
Strongly
agree

.

Neither
agree nor
disagree

.

.

Strongly
disagree

.

Screen patients
for prescription
opioid misuse?

O

O

O

O

O

O

O

Briefly intervene
with feedback
and advice?

O

O

O

O

O

O

O

Refer patients to
treatment
resources if
necessary?

O

O

O

O

O

O

O

Q21 When it comes to screening patients for prescription opioid misuse,
Strongly
agree

.

Neither
agree nor
disagree

.

.

Strongly
disagree

.

I want to do
what my
supervisor
thinks I should
do

O

O

O

O

O

O

O

I want to do
what other
pharmacists
whose opinions I
value think I
should do

O

O

O

O

O

O

O

I want to do
what my
friends/family
think I should do

O

O

O

O

O

O

O
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Q22 When it comes to providing patients feedback and advice about prescription opioid
misuse,
Neither
agree nor
disagree

Strongly
agree

.

I want to do
what my
supervisor
thinks I should
do

O

O

O

O

O

O

O

I want to do
what my
friends/family
think I should do

O

O

O

O

O

O

O

I want to do
what other
pharmacists
whose opinions I
value think I
should do

O

O

O

O

O

O

O

.

.

Strongly
disagree

.

Q23 When it comes to referring patients to additional treatment resources,
Neither
Strongly
Strongly
.
.
agree nor
.
.
disagree
agree
disagree
I want to do
what my
supervisor
thinks I should
do

O

O

O

O

O

O

O

I want to do
what my
friends/family
think I should do

O

O

O

O

O

O

O

I want to do
what other
pharmacists
whose opinions I
value think I
should do

O

O

O

O

O

O

O
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Q24 How much do you agree that your supervisor thinks you should:
Neither
Strongly
.
.
agree nor
.
.
agree
disagree

Strongly
disagree

Screen patients
for prescription
opioid misuse

O

O

O

O

O

O

O

Briefly
intervene with
feedback and
advice about
opioid misuse

O

O

O

O

O

O

O

Refer a patient
to treatment if
needed

O

O

O

O

O

O

O

Q25 How much do you agree that your friends/family think you should:
Strongly
agree

.

Neither
agree nor
disagree

.

.

Strongly
disagree

.

Screen patients
for prescription
opioid misuse

O

O

O

O

O

O

O

Briefly intervene
with feedback
and advice about
opioid misuse

O

O

O

O

O

O

O

Refer a patient
to treatment if
needed

O

O

O

O

O

O

O
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Q26 How much do you agree with this statement: Engaging patients in a discussion
relating to prescription opioid misuse would be easy for me.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q27 How much do you agree with each statement?
Neither
Strongly
agree nor
.
.
agree
disagree

.

Strongly
disagree

.

The decision to
screen patients
for prescription
opioid misuse is
beyond my
control

O

O

O

O

O

O

O

The decision to
briefly intervene
with feedback
and advice is
beyond my
control

O

O

O

O

O

O

O

The decision to
refer patients to
treatment is
beyond my
control

O

O

O

O

O

O

O
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Q28 I am confident in my ability to do the following:
Neither
Strongly
.
.
agree nor
agree
disagree

.

Strongly
disagree

.

Screen patients
for prescription
opioid misuse

O

O

O

O

O

O

O

Briefly intervene
with feedback
and advice about
opioid misuse

O

O

O

O

O

O

O

Refer a patient
to treatment if
needed

O

O

O

O

O

O

O

Q29 Questioning a patient with whom I have a relationship about the legitimacy of an
opioid prescription would be easy for me.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q30 Questioning a patient with whom I have no strong relationship about the
legitimacy of an opioid prescription would be easy.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q31 In the past 30 days, have you:
Yes

No

Screened a patient for
prescription opioid misuse?

O

O

Briefly intervened with
feedback and advice?

O

O

Referred a patient to
additional treatment
resources?

O

O

Q32 In your pharmacy practice, have you ever:
Yes

No

Screened a patient for
prescription opioid misuse?

O

O

Briefly intervened with
feedback and advice?

O

O

Referred a patient to
additional treatment
resources?

O

O

Q33 How much, if any, do you intend to screen patients for prescription opioid misuse?

Extremely
likely

O

O

O

O

O

O

O

Extremely
unlikely

Q34 How much, if any, do you intend to briefly intervene with feedback and advice for
prescription opioid misuse?

Extremely
likely

O

O

O

O

O

O

O

Extremely
unlikely

Q35 How much, if any, do you intend to refer patients to additional treatment resources
when needed?

Extremely
likely

O

O

O

O

O

O

O

Extremely
unlikely
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Q36 Please indicate how much you agree with each statement.
Neither
Strongly
agree
.
.
.
agree
nor
disagree

Strongly
disagree

.

I want to briefly
intervene with
feedback and
advice for
prescription
opioid misuse

O

O

O

O

O

O

O

I want to screen
patients for
prescription
opioid misuse

O

O

O

O

O

O

O

I want to refer
patients to
additional
resources if they
need it

O

O

O

O

O

O

O

Q37 What, if anything, prevents you from screening for opioid misuse, briefly
intervening, referring to treatment? (Please select up to three)
___Lack of time with other job-related duties
___Lack of privacy to discuss with patients
___Lack of reimbursement/compensation
___Repercussions from employer
___Language barrier with patients
___Workflow does not allow
___Lack of knowledge about opioid misuse
___Lack of knowledge about available treatment resources
___Fear of prescribers' response
___Fear of personal harm from the patient
___Limited information about patient's medical history
___Fear of legal liability or litigation
___Fear of losing rapport with patients
___Fear of accidentally stigmatizing patients as addicts
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___Not enough rapport with patient
___Too little or no training
___Patients unwilling to talk/listen
___Do not know how to initiate conversation
___Other (please specify)

80

APPENDIX E
Finalized Theory of Planned Behavior Items

81
Q13. How much do you agree with this statement: Prescription opioid misuse is a
problem in my community?
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Please indicate how much you agree or disagree with each s
Q14. When the validity of an opioid prescription is in question, I believe it would be
useful for a pharmacist to:
Neither
agree
Strongly
Somewhat
Agree
nor
agree
agree
disagree

Somewhat
disagree

Disagree

Strongly
disagree

Screen
patients for
prescription
opioid
misuse

O

O

O

O

O

O

O

Briefly
intervene
by
providing
feedback
and advice

O

O

O

O

O

O

O

Advise
patients to
consult
their
prescriber

O

O

O

O

O

O

O
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Q15 I believe it is a pharmacist's professional duty to screen patients for prescription
opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q16 I believe it is a pharmacist's professional duty to briefly intervene with feedback and
advice when patients show risky prescription opioid use.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q17 Overall, prescribers are more responsible than pharmacists are for screening patients
for prescription opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q18 Overall, prescribers are more responsible than pharmacists are for briefly
intervening with feedback and advice on prescription opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q19 Overall, prescribers are more responsible than pharmacists are for referring people
to treatment for prescription opioid misuse.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q20 Considering pharmacists whose opinions you value, to what extent do you agree
they would:
Strongly
agree

.

Neither
agree nor
disagree

.

.

Strongly
disagree

.

Screen patients
for prescription
opioid misuse?

O

O

O

O

O

O

O

Briefly intervene
with feedback
and advice?

O

O

O

O

O

O

O

Refer patients to
treatment
resources if
necessary?

O

O

O

O

O

O

O

Q21 When it comes to screening patients for prescription opioid misuse,
Strongly
agree

.

Neither
agree nor
disagree

.

.

Strongly
disagree

.

I want to do
what my
supervisor
thinks I should
do

O

O

O

O

O

O

O

I want to do
what other
pharmacists
whose opinions I
value think I
should do

O

O

O

O

O

O

O

I want to do
what my
friends/family
think I should do

O

O

O

O

O

O

O
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Q22 When it comes to providing patients feedback and advice about prescription opioid
misuse,
Neither
agree nor
disagree

Strongly
agree

.

I want to do
what my
supervisor
thinks I should
do

O

O

O

O

O

O

O

I want to do
what my
friends/family
think I should do

O

O

O

O

O

O

O

I want to do
what other
pharmacists
whose opinions I
value think I
should do

O

O

O

O

O

O

O

.

.

Strongly
disagree

.

Q23 When it comes to referring patients to additional treatment resources,
Neither
Strongly
Strongly
.
.
agree nor
.
.
disagree
agree
disagree
I want to do
what my
supervisor
thinks I should
do

O

O

O

O

O

O

O

I want to do
what my
friends/family
think I should do

O

O

O

O

O

O

O

I want to do
what other
pharmacists
whose opinions I
value think I
should do

O

O

O

O

O

O

O
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Q24 How much do you agree that your supervisor thinks you should:
Neither
Strongly
.
.
agree nor
.
.
agree
disagree

Strongly
disagree

Screen patients
for prescription
opioid misuse

O

O

O

O

O

O

O

Briefly
intervene with
feedback and
advice about
opioid misuse

O

O

O

O

O

O

O

Refer a patient
to treatment if
needed

O

O

O

O

O

O

O

Q25 How much do you agree with this statement: Engaging patients in a discussion
relating to prescription opioid misuse would be easy for me.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
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Q26 How much do you agree with each statement?
Neither
Strongly
.
.
agree nor
agree
disagree

.

Strongly
disagree

.

The decision to
screen patients
for prescription
opioid misuse is
beyond my
control

O

O

O

O

O

O

O

The decision to
briefly intervene
with feedback
and advice is
beyond my
control

O

O

O

O

O

O

O

The decision to
refer patients to
treatment is
beyond my
control

O

O

O

O

O

O

O

Q27 I am confident in my ability to do the following:
Neither
Strongly
agree nor
.
.
agree
disagree

.

Strongly
disagree

.

Screen patients
for prescription
opioid misuse

O

O

O

O

O

O

O

Briefly intervene
with feedback
and advice about
opioid misuse

O

O

O

O

O

O

O

Refer a patient
to treatment if
needed

O

O

O

O

O

O

O
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Q28 Questioning a patient with whom I have a relationship about the legitimacy of an
opioid prescription would be easy for me.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q29 Questioning a patient with whom I have no strong relationship about the
legitimacy of an opioid prescription would be easy.
___Strongly agree
___Agree
___Somewhat agree
___Neither agree nor disagree
___Somewhat disagree
___Disagree
___Strongly disagree
Q30 In the past 30 days, have you:
Yes

No

Screened a patient for
prescription opioid misuse?

O

O

Briefly intervened with
feedback and advice?

O

O

Referred a patient to
additional treatment
resources?

O

O
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Q31 In your pharmacy practice, have you ever:
Yes

No

Screened a patient for
prescription opioid misuse?

O

O

Briefly intervened with
feedback and advice?

O

O

Referred a patient to
additional treatment
resources?

O

O

Q32 How much, if any, do you intend to screen patients for prescription opioid misuse?

Extremely
likely

O

O

O

O

O

O

O

Extremely
unlikely

Q33 How much, if any, do you intend to briefly intervene with feedback and advice for
prescription opioid misuse?

Extremely
likely

O

O

O

O

O

O

O

Extremely
unlikely

Q34 How much, if any, do you intend to refer patients to additional treatment resources
when needed?

Extremely
likely

O

O

O

O

O

O

O

Extremely
unlikely
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Q35 Please indicate how much you agree with each statement.
Neither
Strongly
.
.
agree nor
.
agree
disagree

Strongly
disagree

.

I want to briefly
intervene with
feedback and
advice for
prescription
opioid misuse

O

O

O

O

O

O

O

I want to screen
patients for
prescription
opioid misuse

O

O

O

O

O

O

O

I want to refer
patients to
additional
resources if they
need it

O

O

O

O

O

O

O

